Azd8835

The PI3K inhibitors AZD8835, AMG319, HS173, and AS605240 were purchased from Selleck (Houston, TX, USA). The PI3K inhibitors GDC0941, LY294002, and BEZ235 and the Akt inhibitor afuresertib were purchased from MedChemExpress (Monmouth Junction, NJ, USA). Each drug was dissolved with dimethylsulfoxide (DMSO) to a storage solution of 100 mM. We diluted 100 mM of each drug with DMSO to a concentration of 10 mM of drug. BmE cells were seeded in 96-well plates 24 h before treatment with drugs. We added 10 mM of each drug to the cell culture medium at a dilution ratio of 1:1000 (0.1% of total volume) to prepare 10 µM of the drug. BmE cells were incubated with 10 µM of the drugs for 72 h. BmE cells were also incubated with 0 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 40 µM, 80 µM, and 100 µM of AZD8835 for 72 h. Each treatment with drugs and DMSO control comprised three replicates. Cell viability was measured using the CellTiter 96^® AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI, USA) [22 (link)].

Trametinib (Cat.#S2673), alpelisib (Cat.#S2814), pictilisib (Cat.#S1605), AZD8186 (Cat.#S7694), capivasertib (Cat.#S8019), AZD8835 (Cat.#S7966), eganelisib (Cat.#S8330), ferrostatin-1 (Cat.# S7243), and idelalisib (Cat.#S2226) were purchased from Selleckchem (Houston, TX, USA). TGX-221 (Cat.#S528113) was purchased from Merck Millipore (Burlington, MA, USA). Temsirolimus (Cat.#PZ0020) was purchased from Sigma-Aldrich. The inhibitors mentioned above were dissolved in DMSO (Trametinib, alpelisib, pictilisib, AZD8835, eganelisib, idelalisib, AZD8186, capivasertib, TGX-221, and Temsirolimus) and stored at −20 °C.